To investigate whether FGFR4 and EZH2 inhibitors could synergistically repress tumor growth in vivo, we first administered Roblitinib and CPI-169 alone or in combination in the zebrafish HCC primary tumors. The gene discussed is FGFR4; the disease is neoplasm.